Literature DB >> 21763952

Anti-signal recognition particle myopathy in the first decade of life.

Shigeaki Suzuki1, Masayasu Ohta, Yuko Shimizu, Yukiko K Hayashi, Ichizo Nishino.   

Abstract

Autoantibodies to signal recognition particle have been associated with juvenile and adult-onset necrotizing myopathy. However, only a few teenage patients with anti-signal recognition particle myopathy have been reported, and to date, to our knowledge, no patient younger than 10 years has been documented. We describe 2 Japanese girls with anti-signal recognition particle myopathy who developed symptoms from the ages of 5 and 9 years, respectively. Both patients had progressive muscle weakness and atrophy without myalgia. Facioscapulohumeral muscular dystrophy was initially suspected because of asymmetric shoulder girdle muscle involvement in one patient, and limb girdle muscular dystrophy due to proximal limb muscle weakness in the other. There were no extramuscular manifestations, including fever or arthritis. Serum creatine kinase levels were elevated to 2,467-4,629 IU/L. Results of muscle biopsy revealed necrotizing myopathy with minimal to mild endomysial fibrosis but without inflammatory infiltrates. Immunosuppressive agents were not effective for muscle weakness, resulting in marked disability. Anti-signal recognition particle myopathy can occur in the first decade of life and should be included in the differential diagnosis for children with progressive limb girdle muscle weakness and high creatine kinase levels.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21763952     DOI: 10.1016/j.pediatrneurol.2011.04.009

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  9 in total

Review 1.  Use of Rescue Therapy with IVIG or Cyclophosphamide in Juvenile Myositis.

Authors:  Theonymfi Doudouliaki; Charalampia Papadopoulou; Claire T Deakin
Journal:  Curr Rheumatol Rep       Date:  2021-03-08       Impact factor: 4.592

Review 2.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

Review 3.  Immune-Mediated Necrotizing Myopathy.

Authors:  Iago Pinal-Fernandez; Maria Casal-Dominguez; Andrew L Mammen
Journal:  Curr Rheumatol Rep       Date:  2018-03-26       Impact factor: 4.592

Review 4.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Semin Neurol       Date:  2012-11-01       Impact factor: 3.420

5.  Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients.

Authors:  Shigeaki Suzuki; Atsuko Nishikawa; Masataka Kuwana; Hiroaki Nishimura; Yurika Watanabe; Jin Nakahara; Yukiko K Hayashi; Norihiro Suzuki; Ichizo Nishino
Journal:  Orphanet J Rare Dis       Date:  2015-05-13       Impact factor: 4.123

Review 6.  Effective induction therapy for anti-SRP associated myositis in childhood: A small case series and review of the literature.

Authors:  E L Binns; E Moraitis; S Maillard; S Tansley; N McHugh; T S Jacques; L R Wedderburn; C Pilkington; S A Yasin; K Nistala
Journal:  Pediatr Rheumatol Online J       Date:  2017-10-31       Impact factor: 3.054

7.  A child with antibody-negative immune-mediated necrotizing myopathy.

Authors:  Cemal Karakas; Jeetendra Sah; Roberta Seidman; Geetha Chari; Yoshimi Hisamoto; Joan Cracco; Alexandra Reznikov; Radha Giridharan; Yaacov Anziska
Journal:  Muscle Nerve       Date:  2018-11-28       Impact factor: 3.217

8.  The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; Mona Shah; Gulnara Mamyrova; Adam M Huber; Madeline Murguia Rice; Ira N Targoff; Frederick W Miller
Journal:  Medicine (Baltimore)       Date:  2013-07       Impact factor: 1.817

Review 9.  Role of Immunoglobulins in Muscular Dystrophies and Inflammatory Myopathies.

Authors:  Andrea Farini; Chiara Villa; Luana Tripodi; Mariella Legato; Yvan Torrente
Journal:  Front Immunol       Date:  2021-07-14       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.